Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Gross Profit (2016 - 2025)

IGC Pharma (IGC) has disclosed Gross Profit for 16 consecutive years, with $99000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gross Profit fell 50.0% to $99000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $511000.0, a 23.16% decrease, with the full-year FY2025 number at $619000.0, down 15.55% from a year prior.
  • Gross Profit was $99000.0 for Q3 2025 at IGC Pharma, down from $154000.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $255000.0 in Q2 2023 to a low of $26000.0 in Q2 2021.
  • A 5-year average of $119368.4 and a median of $133000.0 in 2023 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: surged 446.15% in 2022, then crashed 50.0% in 2025.
  • IGC Pharma's Gross Profit stood at $62000.0 in 2021, then skyrocketed by 64.52% to $102000.0 in 2022, then surged by 30.39% to $133000.0 in 2023, then fell by 21.8% to $104000.0 in 2024, then dropped by 4.81% to $99000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Gross Profit are $99000.0 (Q3 2025), $154000.0 (Q2 2025), and $154000.0 (Q1 2025).